-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q1 Revenue $13.6M
4:27PM ET 5/12/2022 MT Newswires...
Quotes Snapshot > ALPN
Alpine Immune Sciences Inc ALPN:NASDAQ
Last Price$8.34NASDAQ Previous Close - Last Trade as of 3:58PM ET 5/24/22
Today's Change+0.04(0.48%)
Bid (Size)$8.00 (1)
Ask (Size)$8.33 (11)
Day Low / High$7.98 - 8.50
Volume139.3 K
Read more news Recent News
Alpine Immune Q4 Loss Widens Amid Lower Revenue; Sees Enough Funds Through 2024
5:11PM ET 3/17/2022 MT NewswiresAlpine Immune Sciences (ALPN) on Thursday widened its net loss to $0.52 per share in Q4 from $0.27 per share a year earlier. Analysts polled by Capital IQ...
-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q4 Revenue $4.5M
4:05PM ET 3/17/2022 MT Newswires...
Alpine Says FDA Places Partial Clinical Hold on Study of Davoceticept Drug Cocktail in Advanced Malignancies
9:48AM ET 3/07/2022 MT NewswiresAlpine Immune Sciences (ALPN) said Monday the US Food and Drug Administration placed its clinical study of davoceticept in combination with pembrolizumab...
View all Commentary and Analysis
Alpine: Rest Before Rallying Again
12:08PM ET 4/25/2022 Seeking AlphaAlpine Immune Sciences (ALPN) Investor Presentation - Slideshow
3:44PM ET 1/10/2022 Seeking AlphaAlpine Immune Sciences (ALPN) Investor Presentation
11:29AM ET 8/12/2021 Seeking AlphaAlpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2021 Results - Earnings Call Transcript
10:35PM ET 8/10/2021 Seeking AlphaCompany Profile
Business DescriptionAlpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA. View company web site for more details
| Address | 188 East Blaine Street Seattle, Washington 98102 |
| Phone | +1.206.788.4545 |
| Number of Employees | 48 |
| Recent SEC Filing | 05/24/2022 8-K |
| Executive Chairman & Chief Executive Officer | Mitchell H. Gold |
| President & Head-Research & Development | Stanford L. Peng |
| Finance Director | Thaedra Thullberry |
| Chief Financial Officer, Secretary & Senior VP | James Paul Rickey |
Company Highlights
| Price Open | $8.37 |
| Previous Close | $8.30 |
| 52 Week Range | $6.00 - 14.40 |
| Market Capitalization | $252.9 M |
| Shares Outstanding | 30.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/09/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.97 |
| Beta vs. S&P 500 | N/A |
| Revenue | $705.0 K |
| Net Profit Margin | -214.70% |
| Return on Equity | -59.07% |
Analyst Ratings as of 10/14/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |